Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CGAS | Q8N884 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 8/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.31 |
| ▸ | GLRB | P48167 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17501768 | 0.69 | — | — | |
| SCHEMBL9818953 | 0.67 | POLB (0.46) | LMNAMAPTHSD17B10KMT2A | |
| SCHEMBL11969830 | 0.67 | — | — | |
| Water SCHEMBL6788837 | 0.65 | CGAS (0.44) | CGASLMNAHSD17B10KMT2A | |
| SCHEMBL1997096 | 0.64 | ALPL (0.35) | LMNAMAPT | |
| SCHEMBL5006369 | 0.62 | CGAS (0.42) | CGASLMNA | |
| SCHEMBL16063687 | 0.62 | HSD17B10 (0.45) | CGASLMNAF2MAPTHSD17B10 | |
| SCHEMBL23942726 | 0.61 | SCD (0.37) | KMT2A | |
| SCHEMBL12332375 | 0.61 | GRN (0.38) | CGASLMNAKMT2AGLRA3GLRB | |
| SCHEMBL10765607 | 0.61 | CGAS (0.41) | CGASLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118307564-A | Nitrogen-containing heterocyclic compound, and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-10640466-B2 | Anthracene based compounds and their uses | UNIVERSITY OF HERTFORDSHIRE HIGHER EDUCATION CORPORATION (GB) | 2020-05-05 | — | — | US | disclosed |
| US-20180118685-A1 | ANTHRACENE BASED COMPOUNDS AND THEIR USES | UNIVERSITY OF HERTFORDSHIRE HIGHER EDUCATION CORPORATION (GB) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118685-A1 | ANTHRACENE BASED COMPOUNDS AND THEIR USES | CYP2D6, CYP3A43, ACMSD | CGAS 1375/4885LMNA 823/4885F2 658/4885 |
| US-10640466-B2 | Anthracene based compounds and their uses | CYP2D6, CYP3A43, ACMSD | CGAS 1375/4885LMNA 823/4885F2 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.